|1.||Farrell, M: 4 articles (01/2004 - 01/2001)|
|2.||Ling, Walter: 3 articles (01/2011 - 01/2008)|
|3.||Miotto, Karen: 3 articles (01/2011 - 01/2008)|
|4.||Li, Jing: 3 articles (01/2009 - 01/2008)|
|5.||Ali, R: 3 articles (01/2004 - 01/2001)|
|6.||White, J: 3 articles (01/2004 - 01/2001)|
|7.||Gowing, L: 3 articles (01/2004 - 01/2001)|
|8.||Honey, Brooke L: 2 articles (02/2010 - 09/2009)|
|9.||Miller, Jamie L: 2 articles (02/2010 - 09/2009)|
|10.||Johnson, Peter N: 2 articles (02/2010 - 09/2009)|
|1.||Substance Withdrawal Syndrome (Withdrawal Symptoms)
09/01/2008 - "To demonstrate that lofexidine is well tolerated and effective in the alleviation of observationally defined opioid withdrawal symptoms in opioid dependent individuals undergoing medically supervised opioid detoxification as compared to placebo. "
09/01/2008 - "On the study day 5 MHOWS, subjects treated with lofexidine had significantly lower scores (equating to fewer/less severe withdrawal symptoms) than placebo subjects (least squares means 19.5+/-2.1 versus 30.9+/-2.7; p=0.0019). "
01/01/2009 - "Both treatments significantly reduced withdrawal symptoms by day 3, but there was no significant difference overall between lofexidine and FYP in efficacy or safety. "
09/01/2008 - "Lofexidine is well tolerated and more efficacious than placebo for reducing opioid withdrawal symptoms in inpatients undergoing medically supervised opioid detoxification."
09/01/2008 - "Lofexidine is an alpha-2-adrenergic receptor agonist that is approved in the United Kingdom for the treatment of opioid withdrawal symptoms. "
|2.||Hypotension (Low Blood Pressure)
01/01/1999 - "The objective of this article was to review the data from recently published trials of lofexidine in the treatment of opiate withdrawal, with particular attention to evidence on efficacy, side-effects (particularly hypotension), and the acceptability of this new treatment to the patient population. "
07/01/2001 - "Because lofexidine does not produce hypotension, safe outpatient treatment, without hospital support, could be possible."
01/01/2001 - "The lower incidence of hypotension makes lofexidine more suited to use in outpatient settings than lofexidine. "
01/01/1999 - "Such problems of hypotension as were encountered with lofexidine were adequately managed with dose reduction. "
07/01/2001 - "The subjects treated with lofexidine showed significantly lower levels of withdrawal symptoms, fewer mood problems, less sedation and hypotension. "
|3.||Tic Disorders (Tic Disorder)
03/01/2003 - "Lofexidine appears to be a safe and effective treatment for children with tic disorders and ADHD."
03/01/2003 - "Subjects from a specialty tic disorders clinic were randomly assigned to receive 8 weeks of treatment with lofexidine or placebo under double-blind conditions. "
06/01/2004 - "A placebo-controlled study of lofexidine in the treatment of children with tic disorders and attention deficit hyperactivity disorder."
03/01/2003 - "This study evaluated the efficacy and safety of Lofexidine in treating children with tic disorders and attention deficit hyperactivity disorder (ADHD). "
03/01/2003 - "A placebo-controlled study of lofexidine in the treatment of children with tic disorders and attention deficit hyperactivity disorder."
|5.||Hypertension (High Blood Pressure)
07/01/1986 - "(-)-Lofexidine, a stereoselective alpha 2-adrenoceptor agonist, due to its center of asymmetry, is demonstrated to be a potent drug for the treatment of hypertension (doses 0.561 microgram/kg) and to have the highest affinity and a concentration dependency for alpha 2-adrenoceptors in direct binding studies (0.36 nmol/L). "
12/01/1985 - "Long-term experience with lofexidine in the treatment of mild-to-moderate essential hypertension."
12/01/1983 - "Hemodynamic effect of lofexidine with a diuretic in hypertension."
03/01/1982 - "1 Single oral doses of lofexidine, 0.1, 0.3, and 0.6 mg produced dose related decreases in supine and standing arterial pressure and heart rate in nineteen patients with essential hypertension. "
03/01/1982 - "Antihypertensive effects of lofexidine in patients with essential hypertension."
|1.||Clonidine (ST 155)
|3.||Adrenergic Agonists (Adrenergic Receptor Agonist)
|5.||barbituric acid (barbiturate)
|1.||Chinese Traditional Medicine (Traditional Chinese Medicine)
|2.||Intensive Care (Surgical Intensive Care)
|3.||Drug Therapy (Chemotherapy)